肺癌的诊断治疗进展Advances in the Management of Non Small Cell Lung Cancer.pptVIP

* * ADDITIONAL INFORMATION KEY POINT: * Computer-Generated Tri-Dimensional Structure of the EGFR-ATP Binding Site In the above picture the inhibitor gefitinib occupies the adenosine triphosphate (ATP) cleft The two missense mutations are shown within the activating loop of the tyrosine kinase The three in-frame deletions are all present within another loop which flanks the ATP cleft Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129-2139.